2018-04-09 Project Team Meeting - Agenda & Minutes

Date

10 Apr 2018

Attendees

• Richard Norman (Unlicensed) (Pistoia Alliance)

• Craig Dickinson (Unlicensed) (Eli Lilly)

• Guy Georges (Unlicensed) (Roche)
• Helen Li (Unlicensed) (Eli Lilly)
• Chris Lloyd (Deactivated) (MedImmune)
• Nick Lynch (Unlicensed) (Pistoia Alliance)
• Carmen Nitsche (Deactivated) (Pistoia Alliance)

Discussion items

Minutes

Developability risk prediction proposal

See links in agenda

>Objectives of the current proposal can be summarised as follows:

1. To agree a standard/common way across industry of measuring data for 'well-known' biophysical assays.
2. To share biophysical data generated by the above assays for sets of molecules contributed by industrial partners.
3. To share associated endpoint data (e.g. PK) for the above sets of molecules.
4. Understand whether there is a line of sight (LoS) from biophysical data to endpoint data.

>Link to abstract in the right format for IP3 submission: https://drive.google.com/open?id=1T9KYPkpaNqS1WrSbG8KC5cG5cv6WWQXu

EMBL-EBI  PK prediction workshop

See link to programme in agenda

>EMBL-EBI industrial programme members have an interest in developing a resource with information on Ab molecules (not including sequence and structure information) akin to ChEMBL (https://www.ebi.ac.uk/chembl/).

>Pistoia Alliance is in a position to act as the delivery engine of the workshop output.

>Project has been invited to give a presentation based on our previous and current work. This is a great opportunity to expose and align our thinking and proposed approach with key people across the industry and shape the overall outcome. Input from the team is needed to shape the presentation.

>Richard can attend second day of the workshop and deliver the presentation if needed. We would need some project and/or Pistoia Alliance representation on the first day as well.

>Need to develop our proposal with a view that this could provide a good starting point for a joint project with other industry members.

>In the context of developing our proposal and presentation we need to discuss:

-Is there anything which we would like to contribute to the agenda e.g. other external speakers?

-List of common assays and data which should be part of database. Call out key data and assays which are missing from Adimab paper and which is either critical to decision making or could provide LoS to endpoint data.

-List of common endpoint assays and data.

-Provide common view of rank order by sensitivity of data. There is most interest in data for poorly behaved molecules (associated with and this may be easier to share. Can we pressure test this rank order by getting IP input? What are the sensitivity criteria which IP is measuring against?

-Are there any examples which could be used to highlight the value of data for poorly behaved molecules?

-List of questions and expected challenges.

-What else do we need to move this forward and next steps?

----------

Richard Norman – 10 April 2018